Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty
Phase 2
Completed
- Conditions
- FrailtySarcopeniaAging
- Interventions
- Drug: placebo 600mgDrug: MYMD-1 1050mgDrug: MYMD-1 600MGDrug: MYMD-1 750mgDrug: placebo 900mgDrug: placebo 750mgDrug: placebo 1050mgDrug: MYMD-1 900mg
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- MyMD Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05283486
- Locations
- ๐บ๐ธ
Clinical Research of West Florida, Inc, Clearwater, Florida, United States
๐บ๐ธClinical Research of West Florida, Tampa, Florida, United States
๐บ๐ธJohns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
Single Ascending and Multiple Dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male and Female Adult Subjects
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- MyMD Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05077865
- Locations
- ๐บ๐ธ
Clinical Research of West Florida, Inc, Clearwater, Florida, United States
Single Ascending-dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male Adult Subjects
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- MyMD Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04349761
- Locations
- ๐บ๐ธ
Palm Beach CRO, LLC, West Palm Beach, Florida, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath